Search

Your search keyword '"Tournebize, Juliana"' showing total 49 results
Start Over Author "Tournebize, Juliana"
49 results on '"Tournebize, Juliana"'

3. Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Author

Bouquet, Emilie, Chaouachi, Leila, Chevallier, Cécile, Deheul, Sylvie, Eiden, Céline, Fouilhé, Nathalie, Fournier-Choma, Chistine, Frauger, Elisabeth, Guerlais, Marylène, Le Boisselier, Reynald, Miremont, Ghada, Roussin, Anne, Tournebize, Juliana, Lapeyre-Mestre, Maryse, Boucher, Alexandra, Daveluy, Amélie, Gibaja, Valérie, Jouanjus, Emilie, Mallaret, Michel, Peyrière, Helene, and Micallef, Joëlle

Published
2020
Full Text
View/download PDF

6. Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data

Author

Roussin, Anne, Soeiro, Thomas, Fouque, Charlotte, Jouanjus, Emilie, Frauger, Elisabeth, Fouilhé, Nathalie, Mallaret, Michel, Micallef, Joëlle, Lapeyre-Mestre, Maryse, Batisse, Anne, Chevallier, Cécile, Daveluy, Amélie, Deheul, Sylvie, Fournier-Choma, Christine, Guerlais, Marylène, Le Boisselier, Reynald, Pérault-Pochat, Marie‐christine, Roy, Sophie, Tournebize, Juliana, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Equipe EQUITY, Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), Addictovigilance Grenoble, Centre d'investigation clinique de Toulouse (CIC 1436), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre antipoison et de toxicovigilance (Lyon) (CAPTV Lyon), Hospices Civils de Lyon (HCL), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Addictovigilance de Lille, Service de Pharmacologie Clinique [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Addictovigilance [Caen], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and Agence Nationale de Securite du Medicament et des Produits de Sante, ANSM

Subjects
Adult, Analgesics, Opioid, Male, Pharmacology, Cross-Sectional Studies, Substance-Related Disorders, Humans, Pain, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Pharmacology (medical), France, Tramadol
Abstract

The aim of this paper is to assess recent developments in non-medical tramadol use, tramadol use disorder, illegal procurement and deaths.This study used repeated cross-sectional analysis of data collected nationwide from 2013 to 2018. Analysis was conducted through multisource monitoring of the French Addictovigilance Network of: (1) validated reports of high-risk tramadol use, (2) record systems collecting information from toxicology experts investigating analgesic-related deaths (DTA) and deaths related to substance abuse (DRAMES), and pharmacists for forged prescriptions (OSIAP), and (3) survey of drug users, with investigation of patterns of use while visiting addiction-specialised institutions (OPPIDUM).Despite a plateauing level of tramadol exposure in the French population, the proportion of tramadol reports increased 1.7-fold (187 cases in 2018, 3.2% (95% confidence interval [CI]: 2.74-3.63%), versus 1.9% (95% CI: 1.49-2.42% in 2013). Trends were similar in OSIAP: 11.9% of forged prescriptions in 2018 (95% CI: 10.56-13.45%); 1.7-fold increase; in OPPIDUM: 0.76% (95% CI: 0.55-1.02); 2.2-fold increase; and DRAMES: 3.2% of drug abuse-related deaths in 2018 (95% CI: 1.89-5.16) versus 1.7% in 2013 (95% CI: 0.65-3.84). Tramadol was the primary opioid in analgesic-related deaths in DTA (45% in 2018). Two profiles of high-risk tramadol users were identified: (1) patients treated for pain or with tramadol persistence when pain disappeared (mainly women; mean age 44 years), and (2) individuals with non-medical use for psychoactive effects (mainly men; mean age 36 years).The triangulation of the data obtained through addictovigilance monitoring evidenced a recent increase in high-risk tramadol use. These findings have a practical impact on the limitation of the maximal duration of tramadol prescriptions.

Published
2022

11. Complications liées à l’usage de substances psycho-actives chez les mineurs : cas rapportés au réseau français d’addictovigilance de 2016 à 2021

Author

Menil-Meresse, Césarine, primary, Chaouachi, Leila, additional, Daveluy, Amélie, additional, Fournier-Choma, Christine, additional, Fouilhé, Nathalie, additional, Deheul, Sylvie, additional, Chevalier, Cécile, additional, Lacroix, Clémence, additional, Tournebize, Juliana, additional, Aquizerate, Aurelie, additional, Pain, Stephanie, additional, Ponte, Camille, additional, Batisse, Anne, additional, and Peyriere, Hélène, additional

Published
2022
Full Text
View/download PDF

23. Le mésusage de la cigarette électronique : une centaine de jeunes hospitalisés après avoir vapoté dans le nord-est de la France

Author

Tournebize, Juliana, primary, Gibaja, Valérie, additional, Grossenbacher, Francis, additional, Plenier, Yannick, additional, Medhioub, Yasmine, additional, Batisse, Anne, additional, Le Boisselier, Reynald, additional, Gillet, Pierre, additional, Puskarczyk, Emmanuel, additional, Gaulier, Jean-Michel, additional, and Djerada, Zoubir, additional

Published
2021
Full Text
View/download PDF

30. Hair analysis can support the follow‐up addiction care after acute New Psychoactive Substances intoxication: Illustration by two cases

Author

Lagoutte‐Renosi, Jennifer, primary, Richeval, Camille, additional, Phanithavong, Mélodie, additional, Wiart, Jean‐François, additional, Castex, Eugénie, additional, Vanhoy, Xavier, additional, Hakim, Florian, additional, Deheul, Sylvie, additional, Tournebize, Juliana, additional, Allorge, Delphine, additional, and Gaulier, Jean‐Michel, additional

Published
2020
Full Text
View/download PDF

31. Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Author

Lapeyre-Mestre, Maryse, primary, Boucher, Alexandra, additional, Daveluy, Amélie, additional, Gibaja, Valérie, additional, Jouanjus, Emilie, additional, Mallaret, Michel, additional, Peyrière, Helene, additional, Micallef, Joëlle, additional, Bouquet, Emilie, additional, Chaouachi, Leila, additional, Chevallier, Cécile, additional, Deheul, Sylvie, additional, Eiden, Céline, additional, Fouilhé, Nathalie, additional, Fournier-Choma, Chistine, additional, Frauger, Elisabeth, additional, Guerlais, Marylène, additional, Le Boisselier, Reynald, additional, Miremont, Ghada, additional, Roussin, Anne, additional, and Tournebize, Juliana, additional

Published
2020
Full Text
View/download PDF

32. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017).

Author

Bouquet, Emilie, Pain, Stéphanie, Eiden, Céline, Jouanjus, Emilie, Richard, Nathalie, Fauconneau, Bernard, Pérault‐Pochat, Marie‐Christine, Batisse, Anne, Carton, Louise, Chevalier, Cécile, Daveluy, Amélie, Fournier‐Choma, Christine, Guerlais, Marylène, Le Boisselier, Reynald, Pochard, Liselotte, Revol, Bruno, and Tournebize, Juliana

Subjects
MARIJUANA, SINUS of valsalva, INTRACRANIAL aneurysm ruptures, NEONATAL death, RUPTURED aneurysms, INTRACRANIAL hypertension, SYNTHETIC marijuana
Abstract

Aims: To describe the adverse events (AEs) of recreational cannabis use in France between 2012 and 2017. Methods: AEs related to recreational cannabis use, alone or in combination with alcohol and/or tobacco reported to the French Addictovigilance Network were analysed (excluding cannabidiol and synthetic cannabinoids). Results: Reporting of AEs tripled between 2012 (n = 179, 6.3%, 95% confidence interval [CI] = 5.4–7.2) and 2017 (n = 562, 10.1%, 95% CI = 9.3–10.9), reaching 2217 cases. They concerned mainly men (76.4%) and users aged between 18 and 34 years (18–25: 30.9%; 26–34: 26.3%, range: 12–84 years). Cannabis was mainly inhaled (71.6%) and exposure was most often chronic (64.2%). Many types of AEs were reported: psychiatric (51.2%), neurological (15.6%), cardiac (7.8%) and gastrointestinal (7.7%), including unexpected AEs (n = 34, 1.1%). The most common effect was dependence, ranging from 10.1% (95% CI = 7.9–12.3) to 20.3% (95% CI = 17.3–23.2) over the study period. Cannabinoid hyperemesis syndrome (n = 87, 2.8%) emerged from 2015. Deaths accounted for 0.2% of all AEs (4 men and 3 women aged on average 35 years). A chronic pattern of cannabis use was reported in 4 of them (intracranial hypertension in the context of lung cancer, suicide, cerebral haematoma, neonatal death with concomitant chronic alcohol use), while in the other cases the toxicological analysis identified cannabis use (ruptured aneurysm and unknown aetiology). Conclusion: This study showed a multitude of AEs related to recreational cannabis use, including unexpected AEs and deaths. It highlights the problem of dependence and the emergence of cannabinoid hyperemesis syndrome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Off-Label Use Of Antipsychotics In The French Psychiatric Hospital Of Nancy

Author

Tournebize, Juliana

Abstract

Introduction: Despite treatment guidelines recommending that second generation antipsychotics (SGAs) are preferable and should be used as monotherapy, available literature revealed use of first-generation APs (FGAs), polypharmacy, and use of APs at lower than recommended doses.1,2 In addition, off-label indications of APs are very common.3 Minimal data exist regarding AP off-label use in French psychiatric hospitals. Objectives: The aim of this study was to investigate the frequency and the nature of APs off-label prescribing in a population of hospitalized patients with psychiatric disorder. Methods: Retrospective cohort study utilizing the hospital data base of Centre Psychothu00e9rapique de Nancy from Mars 01,2017 through Mars 03,2017. Only patients with at least one AP prescription were included. Results: 129 patients were included. The majority of patients were men (51%,44u00b116 years). The SGAs (59%) were the most prescribed. Although the majority of patients (74%) received at least one AP, 23% were prescribed two APs, 3 patients three APs and 1 patients four APs (3 SGAs +1 FGAs). In addition, 26% of patients had received APs for off-label indications such as reaction to severe stress (14%), disorders due to psychoactive substance use (4%), depressive episodes (n=4) and specific personality disorders (n=2). The use of AP at lower than recommended doses was also observed (17%). Conclusions: Off-label APs prescription was frequent. Patients frequently received multiple APs and at doses below the recommended guidelines for the management of psychotic disorders without approval for use. When prescribing off-label use, prescribers should carefully evaluate risk/benefit ratio for the individual patient.

Published
2017

43. Intoxications par le dextrométhorphane : données issues des centres antipoison et de toxicovigilance français de janvier 1999 à décembre 2014

Author

Gibaja, Valérie, primary, Boltz, Patricia, additional, Tournebize, Juliana, additional, Labadie, Magali, additional, Boulamery, Audrey, additional, Villa, Antoine, additional, Cardona, Florence, additional, Picot, Cyndie, additional, Saviuc, Philippe, additional, Manel, Jacques, additional, and Kahn, Jean-Pierre, additional

Published
2017
Full Text
View/download PDF

49. [French trends in the misuse of Fentanyl: From 2010 to 2015].

Author

Tournebize J, Gibaja V, Frauger E, Authier N, Seyer D, Perri-Plandé J, Fresse A, Gillet P, Javot L, and Kahn JP

Subjects
Administration, Cutaneous, Analgesics, Opioid adverse effects, Female, Fentanyl adverse effects, Humans, Male, Chronic Pain drug therapy, Chronic Pain epidemiology, Neoplasms drug therapy, Neoplasms epidemiology
Abstract

Objectives: The aim of this study was to evaluate the French use, misuse and abuse/dependence of non-injectable forms of fentanyl (transdermal and transmucosal fentanyl formulations)., Methods: Problematic use of transdermal and transmucosal fentanyl formulations was evaluated using an approach combining multiple sources of information: (1) spontaneous notifications recorded during 6 years (2010-2015) for transdermal fentanyl form and 3 years for transmucosal fentanyl forms and (2) data from annual epidemiological systematic surveys conducted by the French Addictovigilance Network during 6 years (2010-2015)., Results: In all, 147 cases were notified for transdermal fentanyl formulation and 109 cases for transmucosal fentanyl formulations. According to the galenic formulation, analysis of these cases emphasizes different profiles: for transdermal fentanyl formulation, two consumption profiles: 1/mainly for analgesic effects (74 %): women (61 %), 47 years, with addictive and/or psychiatric history (46 %), treated for chronic non-cancer related pain (93 %), 2/seeking positive psychic effects other than analgesia (26 %): men (82 %), 32 years, with addictive and/or psychiatric history (87 %) and having obtained the fentanyl patch illegally (60 %) for non-medical use. For transmucosal fentanyl formulations, only one consumption profile was observed: women (52 %), 48 years, with addictive (24 %) and/or psychiatric history (28 %), off label indication (72 %) (indications for non-cancer pain and/or no or insufficient opioid background treatment). The misuse of transmucosal fentanyl formulations implies a high risk of adverse effects: those already known of opioid-based drugs, sometimes lethal (withdrawal syndrome, respiratory and central nervous system depression…) but also serious reactions at the application site (buccal or nasal). For the transdermal fentanyl formulation, 27 cases (18 %) of involuntary intoxication were observed, of which 25 were serious. Nineteen deaths involving both forms of fentanyl have been reported (2 for the transmucosal formulations and 17 for the transdermal formulation)., Conclusion: Our results report significant and worrying misuse of transmucosal fentanyl formulations with wide off-label use and also primary dependence on fentanyl, regardless of galenic formulation, in patients treated for chronic non cancer pain. Given the significant risks of fentanyl, it is necessary to continue the monitoring of misuse, in particular, thanks to the activities of the French Addictovigilance network allowing a multisource approach and who provides information concerning cases of abuse, misuse and dependence., (Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results